Stockreport

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma, Inc.  (ATYR) 
PDF Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in [Read more]